Elanco (ELAN) CEO Jeffrey Simmons awarded new deferred stock units

(Neutral)

Form Type

Rhea-AI Filing Summary

Elanco Animal Health President and CEO Jeffrey N. Simmons reported an acquisition of deferred stock units as part of his compensation. He received 110.8583 deferred stock units on Company common stock at a reference price of $24.98 per unit, described as a grant or award. After this award, his direct holdings of deferred stock units total 19,179.7639 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and they settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simmons Jeffrey N

Role PRESIDENT, CEO AND DIRECTOR

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	110.8583	$24.98	$3K

Holdings After Transaction: Deferred Stock Units — 19,179.7639 shares (Direct)

Footnotes (2)

F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/24/2026 - 04:44 PM

FAQ

What insider transaction did Elanco (ELAN) report for Jeffrey Simmons?

Elanco (ELAN) reported that President and CEO Jeffrey N. Simmons acquired 110.8583 deferred stock units as a grant or award. These units are part of his compensation and increase his total deferred stock unit holdings to 19,179.7639 units.

What are the key terms of the deferred stock units granted at Elanco (ELAN)?

Each Elanco deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent. The units were granted at a reference price of $24.98 and are structured as a compensation award to the President and CEO.

When do Elanco (ELAN) deferred stock units for Jeffrey Simmons settle?

Elanco deferred stock units for Jeffrey N. Simmons settle in cash or Company common stock after termination of employment or in a specified future year. Settlement timing is determined under the Executive Deferral and Stock Match Plan’s provisions.

How many deferred stock units does Elanco (ELAN) CEO hold after this Form 4?

After this transaction, Elanco President and CEO Jeffrey N. Simmons directly holds 19,179.7639 deferred stock units. This total reflects the newly granted 110.8583 units added to his prior balance, as disclosed in the Form 4 filing.

Is the Elanco (ELAN) Form 4 for Jeffrey Simmons a stock purchase or a compensation award?

The Elanco Form 4 for Jeffrey N. Simmons reflects a compensation-related grant, not an open-market stock purchase. The transaction code is “A,” described as a grant, award, or other acquisition of deferred stock units tied to Company common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last)

(First)

(Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS

46221

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	⁽¹⁾	02/20/2026		A		110.8583		⁽²⁾	⁽²⁾	Common Stock	110.8583	$24.98	19,179.7639	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR